Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- western blotting blots signaling signalling WB ICC immunocytochemistry controls proteins prostaglandins PGs PGD2 synthesized PGH2 non-hematopoietic lipocalin-types biological functions G protein-coupled receptors DP1 Gi Gq subunits calcium Ca2+ cells migration up-regulate regulation molecules mRNA unglycosylateds 44 proteins coupled
- Product Overview:
To be used in conjunction with Cayman’s CRTH2/DP2 Receptor (C-Term) polyclonal antibody (Catalog No. 10007002) to block protein-antibody complex formation during immunochemical analysis of CRTH2 · Prostaglandin D2 (PGD2) is synthesized from PGH2 by hematopoietic- and lipocalin-type PGD synthases. PGD2 elicits its biological function through interaction with two distinct G protein-coupled receptors, DP1 and CRTH2/DP2. CRTH2 primarily couples to Gi or Gq subunits to mobilize Ca2+, induce cell migration, and up-regulate adhesion molecules.{11493} CRTH2 mRNA has been detected in various tissues including liver, lung, kidney, brain, heart, thymus, and spleen and in various cell lineages including both hematopoietic and non-hematopoietic cell lines.{9767} Human CRTH2 is 395 amino acids in length with an estimated molecular weight of 43 kDa. Cayman Chemical’s CRTH2/DP2 receptor (N-Term) polyclonal antibody can be used for western blot and immunohistochemical analysis of CRTH2 on samples of human, bovine, murine, and rat origin. It detects both unglycosylated and glycosylated protein at sizes ranging from 35-40 kDa to 50-70 kDa, as reported by Nagata et al., in 1999.{9770}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.